Gabriella Andreotti1, Stella Koutros1, Jonathan N Hofmann1, Dale P Sandler2, Jay H Lubin3, Charles F Lynch4,5, Catherine C Lerro1, Anneclaire J De Roos6, Christine G Parks2, Michael C Alavanja7, Debra T Silverman1, Laura E Beane Freeman1. 1. Occupational and Environmental Epidemiology Branch. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC. 3. Biostatistics Branch. 4. Department of Epidemiology, University of Iowa, Iowa City, IA. 5. State Health Registry of Iowa, Iowa City, IA. 6. Department of Environmental and Occupational Health, Drexel University Dornsife School of Public Health, Philadelphia, PA. 7. Formerly of Occupational and Environmental Epidemiology Branch.
Abstract
Background: Glyphosate is the most commonly used herbicide worldwide, with both residential and agricultural uses. In 2015, the International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans," noting strong mechanistic evidence and positive associations for non-Hodgkin lymphoma (NHL) in some epidemiologic studies. A previous evaluation in the Agricultural Health Study (AHS) with follow-up through 2001 found no statistically significant associations with glyphosate use and cancer at any site. Methods: The AHS is a prospective cohort of licensed pesticide applicators from North Carolina and Iowa. Here, we updated the previous evaluation of glyphosate with cancer incidence from registry linkages through 2012 (North Carolina)/2013 (Iowa). Lifetime days and intensity-weighted lifetime days of glyphosate use were based on self-reported information from enrollment (1993-1997) and follow-up questionnaires (1999-2005). We estimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) using Poisson regression, controlling for potential confounders, including use of other pesticides. All statistical tests were two-sided. Results: Among 54 251 applicators, 44 932 (82.8%) used glyphosate, including 5779 incident cancer cases (79.3% of all cases). In unlagged analyses, glyphosate was not statistically significantly associated with cancer at any site. However, among applicators in the highest exposure quartile, there was an increased risk of acute myeloid leukemia (AML) compared with never users (RR = 2.44, 95% CI = 0.94 to 6.32, Ptrend = .11), though this association was not statistically significant. Results for AML were similar with a five-year (RRQuartile 4 = 2.32, 95% CI = 0.98 to 5.51, Ptrend = .07) and 20-year exposure lag (RRTertile 3 = 2.04, 95% CI = 1.05 to 3.97, Ptrend = .04). Conclusions: In this large, prospective cohort study, no association was apparent between glyphosate and any solid tumors or lymphoid malignancies overall, including NHL and its subtypes. There was some evidence of increased risk of AML among the highest exposed group that requires confirmation.
Background: Glyphosate is the most commonly used herbicide worldwide, with both residential and agricultural uses. In 2015, the International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans," noting strong mechanistic evidence and positive associations for non-Hodgkin lymphoma (NHL) in some epidemiologic studies. A previous evaluation in the Agricultural Health Study (AHS) with follow-up through 2001 found no statistically significant associations with glyphosate use and cancer at any site. Methods: The AHS is a prospective cohort of licensed pesticide applicators from North Carolina and Iowa. Here, we updated the previous evaluation of glyphosate with cancer incidence from registry linkages through 2012 (North Carolina)/2013 (Iowa). Lifetime days and intensity-weighted lifetime days of glyphosate use were based on self-reported information from enrollment (1993-1997) and follow-up questionnaires (1999-2005). We estimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) using Poisson regression, controlling for potential confounders, including use of other pesticides. All statistical tests were two-sided. Results: Among 54 251 applicators, 44 932 (82.8%) used glyphosate, including 5779 incident cancer cases (79.3% of all cases). In unlagged analyses, glyphosate was not statistically significantly associated with cancer at any site. However, among applicators in the highest exposure quartile, there was an increased risk of acute myeloid leukemia (AML) compared with never users (RR = 2.44, 95% CI = 0.94 to 6.32, Ptrend = .11), though this association was not statistically significant. Results for AML were similar with a five-year (RRQuartile 4 = 2.32, 95% CI = 0.98 to 5.51, Ptrend = .07) and 20-year exposure lag (RRTertile 3 = 2.04, 95% CI = 1.05 to 3.97, Ptrend = .04). Conclusions: In this large, prospective cohort study, no association was apparent between glyphosate and any solid tumors or lymphoid malignancies overall, including NHL and its subtypes. There was some evidence of increased risk of AML among the highest exposed group that requires confirmation.
Authors: A J De Roos; S H Zahm; K P Cantor; D D Weisenburger; F F Holmes; L F Burmeister; A Blair Journal: Occup Environ Med Date: 2003-09 Impact factor: 4.402
Authors: L M Brown; A Blair; R Gibson; G D Everett; K P Cantor; L M Schuman; L F Burmeister; S F Van Lier; F Dick Journal: Cancer Res Date: 1990-10-15 Impact factor: 12.701
Authors: Laura E Beane Freeman; Matthew R Bonner; Aaron Blair; Jane A Hoppin; Dale P Sandler; Jay H Lubin; Mustafa Dosemeci; Charles F Lynch; Charles Knott; Michael C R Alavanja Journal: Am J Epidemiol Date: 2005-10-19 Impact factor: 4.897
Authors: L Orsi; L Delabre; A Monnereau; P Delval; C Berthou; P Fenaux; G Marit; P Soubeyran; F Huguet; N Milpied; M Leporrier; D Hemon; X Troussard; J Clavel Journal: Occup Environ Med Date: 2008-11-18 Impact factor: 4.402
Authors: Linda Kachuri; Paul A Demers; Aaron Blair; John J Spinelli; Manisha Pahwa; John R McLaughlin; Punam Pahwa; James A Dosman; Shelley A Harris Journal: Int J Cancer Date: 2013-05-02 Impact factor: 7.396
Authors: Sonya L Heltshe; Jay H Lubin; Stella Koutros; Joseph B Coble; Bu-Tian Ji; Michael C R Alavanja; Aaron Blair; Dale P Sandler; Cynthia J Hines; Kent W Thomas; Joseph Barker; Gabriella Andreotti; Jane A Hoppin; Laura E Beane Freeman Journal: J Expo Sci Environ Epidemiol Date: 2012-05-09 Impact factor: 5.563
Authors: Catherine C Lerro; Jonathan N Hofmann; Gabriella Andreotti; Stella Koutros; Christine G Parks; Aaron Blair; Paul S Albert; Jay H Lubin; Dale P Sandler; Laura E Beane Freeman Journal: Int J Epidemiol Date: 2020-08-01 Impact factor: 7.196
Authors: Catherine C Lerro; Stella Koutros; Gabriella Andreotti; Dale P Sandler; Charles F Lynch; Lydia M Louis; Aaron Blair; Christine G Parks; Srishti Shrestha; Jay H Lubin; Paul S Albert; Jonathan N Hofmann; Laura E Beane Freeman Journal: Cancer Causes Control Date: 2019-02-25 Impact factor: 2.506
Authors: Gabriella Andreotti; Jay H Lubin; Stella Koutros; Jonathan N Hofmann; Dale P Sandler; Catherine C Lerro; Christine G Parks; Debra T Silverman; Laura E Beane Freeman Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Linda K Ko; Sou H Jang; Daniela B Friedman; Karen Glanz; Jennifer Leeman; Peggy A Hannon; Jackilen Shannon; Allison Cole; Rebecca Williams; Thuy Vu Journal: Prev Med Date: 2019-08-31 Impact factor: 4.018
Authors: Luoping Zhang; Iemaan Rana; Rachel M Shaffer; Emanuela Taioli; Lianne Sheppard Journal: Mutat Res Rev Mutat Res Date: 2019-02-10 Impact factor: 5.657